The efficacy of the Peginterferon treatment in chronic hepatitis HDV and compensate liver cirrhosis

To evaluate the efficiency of the treatment with Peginterferon alfa 2a 180 mcg/week, 48 weeks in patients with chronic hepatitis or compensated liver cirrhosis HDV and predictive factors of response to treatment. Prospective study that enrolled 50 patients with chronic hepatitis or compensated cirrh...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 2014-04, Vol.118 (2), p.368-375
Hauptverfasser:	Tugui, Letitia, Dumitru, M, Iacob, Speranta, Gheorghe, Liana, Preda, Carmen, Dinu, Ioana, Becheanu, G, Dumbrava, Mona, Nicolae, Ioana, Andrei, Adriana, Lupu, A, Diculescu, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Female Hepatitis D, Chronic - diagnosis Hepatitis D, Chronic - drug therapy Hepatitis D, Chronic - virology Hepatitis Delta Virus - genetics Hepatitis Delta Virus - isolation & purification Humans Interferon-alpha - adverse effects Interferon-alpha - therapeutic use Liver Cirrhosis - diagnosis Liver Cirrhosis - drug therapy Liver Cirrhosis - virology Male Middle Aged Polyethylene Glycols - adverse effects Polyethylene Glycols - therapeutic use Prospective Studies Recombinant Proteins - adverse effects Recombinant Proteins - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!